HSBC Holdings’s Astria Therapeutics ATXS Stock Holding History

HSBC Holdings’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,655	Closed	-$323K	–	2905
2025 Q4	$323K	Sell	24,655 -56,528	-70%	-$675K	﹤0.01%	2502
2025 Q3	$590K	Buy	81,183 +20,332	+33%	+$138K	﹤0.01%	2021
2025 Q2	$335K	Buy	60,851 +28,043	+85%	+$136K	﹤0.01%	2375
2025 Q1	$174K	Buy	32,808 +13,545	+70%	+$94.8K	﹤0.01%	2655
2024 Q4	$170K	Buy	19,263 +1,587	+9%	+$16.9K	﹤0.01%	2764
2024 Q3	$195K	Sell	17,676 -1,097	-6%	-$12.2K	﹤0.01%	2623
2024 Q2	$171K	Buy	+18,773	New	+$183K	﹤0.01%	2613

HSBC Holdings's ATXS Position: Q1 2026 in Review

HSBC Holdings sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 24,655 shares — an estimated $323K sold.

HSBC Holdings first reported a position in ATXS in Q2 2024 and held it in 7 quarters. The position peaked at $590K in Q3 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

HSBC Holdings reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
HSBC Holdings sold 24,655 Astria Therapeutics shares in Q1 2026, an estimated $323K.
HSBC Holdings first reported a position in Astria Therapeutics in Q2 2024 and held it in 7 quarters.
HSBC Holdings's Astria Therapeutics position peaked at $590K in Q3 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.